evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

19 questions · 20 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 10%GRADE not reported 1 · 5%Very low 0 · 0%Low 9 · 45%Moderate 5 · 25%High 3 · 15%

Chondroitin vs placebo

Pain on a 0 to 100 mm scale ‐ Short‐term studies (< 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).

1 finding from 1 review

Chondroitin vs placebo

Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

Withdrawals due to adverse events · patients with osteoarthritis

Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin with or without glucosamine vs placebo or control

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).

1 finding from 1 review

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis

Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).

1 finding from 1 review